Indivior Pharmaceuticals (INDV) Q1 FY26 earnings call

Indivior Pharmaceuticals delivered a strong first quarter, driven by robust U.S. SUBLOCADE performance and improved commercial execution, leading to a significant raise in its 2026 financial guidance. The company also strategically managed its debt and returned capital to shareholders through share repurchases. While two pipeline assets were discontinued internally, the focus remains on accelerating SUBLOCADE growth and pursuing commercial-stage business development opportunities to diversify its portfolio.